SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ( GRAVID ).Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma...

Full description

Bibliographic Details
Authors: Gonzalez-Cao, M. (María)|||/items/a92f6c0c-bc3c-46c9-9d59-a6174bc08c57, Puertolas, T. (Teresa)|||/items/95b9743f-10df-4b17-acb4-54380eae921b, Martínez-Vila, C. (Clara)|||/items/009e1dde-8f36-4846-8d02-aa5df7763f7a, Carrera, C. (Cristina)|||/items/b2b30951-9794-4e2c-b1fc-67deca3dc904, Maldonado-Seral, C. (Cayetana)|||/items/c70b4278-c62b-4e02-a133-4a4b295d8361, Rodríguez-Jiménez, P. (Pedro)|||/items/0d9829ad-af7d-49f2-b7ac-3a7f972cad69, Sequero, S. (Silvia)|||/items/b7436e0f-ee98-420c-87d8-d660ca58bb40, Cerezuela, P. (Pablo)|||/items/fb9dae32-027b-4667-a57b-f68b0ea4b317, Feltes-Ochoa, R. (Rosa)|||/items/2048c4da-b218-4d55-9bcd-2511713863ae, Muñoz, E. (Eva)|||/items/8d333e78-2196-41f9-be63-bb2b042d6dcb, Antoñanzas-Basa, M. (Mónica)|||/items/87066fea-e8d0-478b-bf27-df29b6a34483, Martin-Liberal, J. (Juan)|||/items/191ba5ff-b020-4ee7-acab-9054b71f30e7, Soria, A. (Ainara)|||/items/7d7871c8-9615-4064-96aa-c7c20bd468c8, Rodríguez-Moreno, J.F. (Juan Francisco)|||/items/ab38ee72-1bde-4ac2-940b-da52647e50ce, Marquez-Rodas, I. (Iván)|||/items/a59fa425-b0b0-47e3-9eb6-0543b7132a0c, López-Criado, P. (Pilar)|||/items/50be5da1-05ff-47c4-be10-55bf2b1b8db6, Manzano, J.L. (José Luis)|||/items/a7d94d1e-a369-4925-bb9c-e0b5a2b2a2b7, López-Castro, R. (Rafael)|||/items/b7219b44-8e09-43bf-9e5f-82e906eaf7d0, Ayala-De-Miguel, P. (Pablo)|||/items/b6902b57-a950-484f-9b3d-d651b2657d4a, Villalobos, L. (Laura)|||/items/7f8908bf-e4e7-442c-ad6c-97922084447c, Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc, González-Barrallo, I. (Inés)|||/items/041205e9-efbd-45b3-85be-3f5a2ddc61a8, Boada, A. (Aram)|||/items/ca58451b-0978-4bc9-9e70-6a50b4d4a419, García-Castaño, A. (Almudena)|||/items/1846e15d-bb10-4bc1-a11d-4bf0d56261d9, Puig, S. (Susana)|||/items/f5bf96b2-0655-4cd1-b4fe-f39d9e28a6f4, Crespo, G. (Guillermo)|||/items/0a956c2d-2ab1-46ca-bd33-c7a904a8c5fd, Luna-Fra, P. (Pablo)|||/items/f0d73498-ba06-4e5e-b602-d82c4653d5a0, Aguayo-Zamora, C. (Cristina)|||/items/4afb9422-db9f-41e3-a7c2-2ac11a7cd94a, Feito-Rodríguez, M. (Marta)|||/items/c265e484-6f78-4679-9939-0b14de816941, Valles, L. (Lara)|||/items/86485e1e-c9d1-4299-93f1-76d7d34eb0c0, Drozdowskyj, A. (Ana)|||/items/6bf1ad03-c22f-4879-99a4-614a5cbfa233, Gardeazabal, J. (Jesús)|||/items/7ca29a72-ddba-4654-b168-fc78ea6c2241, Fernández-Morales, L.A. (Luis Antonio)|||/items/705eb078-7c65-4588-90e5-b836d540ba30, Rodrigo, A. (Alberto)|||/items/49847272-511d-4e29-a5b2-8d93ba80e5cb, Cruz, R. (Raquel)|||/items/fbb2014d-6893-4e81-a586-ac4d3ede0b20, Yelamos, O. (Oriol)|||/items/6e1a48ca-5c4f-47a3-8054-42865b2e78d1, Rubio, B. (Belén)|||/items/c148cf34-0263-4f9d-ad16-9c28cde5e06f, Mujica, K. (Karmele)|||/items/7c4e8a59-0aa2-434b-a4c9-03582f661ae8, Provencio, M. (Mariano)|||/items/444efafb-9653-49ed-831f-4142bebce8c3, Berrocal, A. (Alfonso)|||/items/1d12d4cb-30ab-4427-bf32-850bdd2f8042
Format: article
Publication Date:2023
Country:España
Institution:Universidad de Navarra
Repository:Dadun. Depósito Académico Digital de la Universidad de Navarra
Language:English
OAI Identifier:oai:dadun.unav.edu:10171/65982
Online Access:https://hdl.handle.net/10171/65982
Access Level:Open access
Keyword:Cancer
COVID-19
Immunotherapy
Melanoma
PD-1
Description
Summary:Background The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ( GRAVID ).Methods The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021.Results One hundred-fifty cases were registered. Median age was 68 years (range 6-95), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: February-May 2020, August-November 2020, and December 2020-April 2021. The first wave had the highest number of registered cases and COVID-19 mortality.Conclusion Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection.